Deciphering the prognostic significance of autoimmune disorders in myelodysplastic syndromes
Letter to the Editor
- 19 Downloads
It is now clear that myelodysplastic syndromes (MDS) are associated with several immune abnormalities [ 1, 2] beside an increased frequency of autoimmune disorders (AD) [ 3]. Montoro and colleagues interestingly analysed the prevalence, clinical characteristics, and outcomes of 142 patients with MDS and AD showing that their overall survival (OS) was inferior even in multivariate analysis and this detrimental effect was confined to patients with clinical rather than laboratoristic manifestations [ 4]. Although these findings are extremely relevant, it is worth mentioning, as shown in Table 1, that the prognostic significance of AD in MDS patients is still debated. In fact, some more studies apparently suggested a potential negative prognostic impact. Among 153 patients, 19 of which developed AD, the survival of subjects with immune abnormalities was significantly worse, as these patients tended to die more frequently of infection or leukemic progression [ 5]. Among 117 MDS...
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 4.Montoro J, Gallur L, Merchán B, Molero A, Roldán E, Martínez-Valle F, Villacampa G, Navarrete M, Ortega M, Castellví J, Saumell S, Bobillo S, Bosch F, Valcárcel D (2018) Autoimmune disorders are common in myelodysplastic syndrome patients and confer an adverse impact on outcomes. Ann Hematol 97(8):1349–1356CrossRefGoogle Scholar
- 11.Mekinian A, Grignano E, Braun T, Decaux O, Liozon E, Costedoat-Chalumeau N, Kahn JE, Hamidou M, Park S, Puéchal X, Toussirot E, Falgarone G, Launay D, Morel N, Trouiller S, Mathian A, Gombert B, Schoindre Y, Lioger B, de Wazieres B, Amoura Z, Buchdaul AL, Georgin-Lavialle S, Dion J, Madaule S, Raffray L, Cathebras P, Piette JC, Rose C, Ziza JM, Lortholary O, Montestruc F, Omouri M, Denis G, Rossignol J, Nimubona S, Adès L, Gardin C, Fenaux P, Fain O (2016) Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study. Rheumatology (Oxford) 55(2):291–300CrossRefGoogle Scholar
- 14.Fozza C, Corda G, Barraqueddu F, Virdis P, Contini S, Galleu A, Isoni A, Dore F, Angelucci E, Longinotti M (2015) Azacitidine improves the T-cell repertoire in patients with myelodysplastic syndromes and acute myeloid leukemia with multilineage dysplasia. Leuk Res 39(9):957–963CrossRefGoogle Scholar
© Springer-Verlag GmbH Germany, part of Springer Nature 2018